U.S. Patent Office Rejects Patents On Gilead’s Antiretroviral Viread (Medical News Today)
U.S. Patent Office Rejects Patents On Gilead’s Antiretroviral Viread (Medical News Today)
The U.S. Patent and Trademark Office on Wednesday rejected four patents on Gilead Sciences’ antiretroviral drug Viread, Reuters reports. Viread is known generically as tenofovir and is sold as part of Gilead’s combination therapies Truvada and Atripla.